Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation-Reference-Cited by-同舟云学术

Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation

Published:2022-03 Issue:3 Volume:22 Page:209-220
ISSN:1568-0096
Container-title:Current Cancer Drug Targets
language:en
Short-container-title:CCDT

Author:

Denny William A.¹^ORCID

Affiliation:

1. Auckland Cancer Society Research Centre, School of Medical Sciences, Private Bag 92019, Auckland 1142, New Zealand | Maurice Wilkins Centre, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

Abstract

Abstract: The p38 MAP kinases are a sub-family of the broad group of mitogen-activated serinethreonine protein kinases. The best-characterised, most widely expressed, and most targeted by drugs is p38α MAP kinase. This review briefly summarises the place of p38α MAP kinase in cellular signalling and discusses the structures and activity profiles of representative examples of the major classes of inhibitors and activators (both synthetic compounds and natural products) of this enzyme. Primary screening was direct in vitro inhibition of isolated p38α enzyme.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference80 articles.

1. Cuenda A.; Rousseau S.; p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007,1773(8),1358-1375

2. Zarubin T.; Han J.; Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005,15(1),11-18

3. Canovas B.; Nebreda A.R.; Diversity and versatility of p38 kinase signalling in health and disease. Nat Rev Mol Cell Biol 2021,22(5),346-366

4. Wagner E.F.; Nebreda A.R.; Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009,9(8),537-549

5. Braicu C.; Buse M.; Busuioc C.; Drula R.; Gulei D.; Raduly L.; Rusu A.; Irimie A.; Atanasov A.G.; Slaby O.; Ionescu C.; Berindan-Neagoe I.; A comprehensive review on MAPK: A promising therapeutic target in cancer. Cancers (Basel) 2019,11(10),1618

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polyamine Dysregulation and Nucleolar Disruption in Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-04-02

2. Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via the ERK1/2 and p38 MAPK Signaling Pathways;Current Molecular Pharmacology;2024-01-11

3. Novel 4-chloro-N-phenyl Benzamide Derivatives as p38α Mitogenactivated Protein Kinase Inhibitors for Treating Cancer, COVID-19, and Other Diseases;Recent Patents on Anti-Cancer Drug Discovery;2023-11

4. Artesunate alleviates 5-fluorouracil-induced intestinal damage by suppressing cellular senescence and enhances its antitumor activity;Discover Oncology;2023-07-27

5. Mitogen activated protein kinase phosphatase 5 alleviates liver ischemia–reperfusion injury by inhibiting TAK1/JNK/p38 pathway;Scientific Reports;2023-07-10